Is PARD3 p.Cys191Phe (c.572G>T) pathogenic?

PARD3 p.Cys191Phe (c.572G>T) is classified Uncertain significance in PARD3 (ClinVar, No assertion criteria, 1 submitter). AlphaMissense: likely benign (0.0867); Absent from gnomAD v4.1; Associated with prostate cancer.

What condition is associated with PARD3 p.Cys191Phe (c.572G>T)?

PARD3 p.Cys191Phe (c.572G>T) is associated with prostate cancer (ClinVar).

How common is PARD3 p.Cys191Phe (c.572G>T) in the general population?

PARD3 p.Cys191Phe (c.572G>T) is absent from gnomAD v4.1 (gnomAD).

What do computational predictors say about PARD3 p.Cys191Phe (c.572G>T)?

AlphaMissense predicts likely benign (score 0.0867) — an in-silico prediction, not a clinical call.

PARD3 p.Cys191Phe

c.572G>T · rs193920777 · VCV161555

Uncertain significance No assertion criteria

Classification

Uncertain significance

ClinVar

Review

No assertion criteria ☆☆☆☆

ClinVar · 1 submitter

AlphaMissense

likely benign

0.0867 · ACMG-weighted

gnomAD v4.1

Absent

absent from gnomAD v4.1

Missense predictors

0/3 damaging

AlphaMissense, REVEL, SaProt

Conditions

prostate cancer

Computational evidence

Protein change
AlphaMissense	0.0867	likely benign
REVEL	0.102	moderately benign-leaning
SaProt	LLR -3.98	tolerated
⇒ AlphaMissense, REVEL and SaProt all call this tolerated.
Splicing
SpliceAI	<0.2	no splice effect predicted · four deltas, not one · how we know
Constraint at this position
Conservation	phyloP 5.8	GERP 2, phastCons 1
Regional constraint	o/e 0.96	unconstrained · MANE · 406 kb · p 0.14 · regional, not allelic
Overall
CADD	23.0	PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean tolerated — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

Variant & gene context

Gene: PARD3
Protein: p.Cys191Phe
Coding: c.572G>T
MANE Select: NM_001184785
dbSNP: rs193920777
Type: single nucleotide variant
Location: chr10:34470095 (GRCh38)
Gene constraint: LOEUF 0.61 · pLI <0.01 (gnomAD)
Structure: AlphaFold pLDDT 54.37 · 1 PDB
Residue 191: the 'disordered' region

Full PARD3 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

prostate cancer — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Similar variants

PARD3 p.Cys191Trp Uncertain significance ⚠ same residue
PARD3 p.Cys191= Likely benign same residue
PARD3 p.Met228Ile Uncertain significance ⚠ same condition
PARD3 c.2560+10A>G Benign ★★ same type
PARD3 p.Ala934Val Benign ★★ same type
PARD3 p.Glu107Asp Benign ★★ same type
PARD3 p.Glu1252= Benign/Likely benign ★★ same type
PARD3 p.Ser798Asn Benign ★★ same type

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/pard3-p-cys191phe (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown